We tested the hypothesis that stimulation of
adiponectin receptors with the synthetic agonist
AdipoRon suppresses proliferation and induces apoptotic death in human high grade serous ovarian tumor cell lines and in ex vivo primary
tumors, mediated by activation of
5' AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of
rapamycin (mTOR). We determined the effect of
AdipoRon on high grade serous ovarian
tumor cells lines (OVCAR3, OVCAR4, A2780) and ex vivo primary
tumor tissue. Western blotting analysis was performed to examine changes in activation of AMPK and mTOR signaling and flow cytometry was utilized to examine changes in cell cycle progression. Immunofluorescence of cleaved
caspase-3 positive cells and flow cytometry of
annexin V positive cells were used to determine changes in apoptotic response. The CyQUANT proliferation assay was used to assess cell proliferation.
AdipoRon treatment increased AMPK phosphorylation (OVCAR3 P = 0.01; A2780 P = 0.02) but did not significantly alter mTOR activity.
AdipoRon induced G1 cell cycle arrest in OVCAR3 (+ 12.1%, P = 0.03) and A2780 (+ 12.0%, P = 0.002) cells. OVCAR3 and OVCAR4 cells treated with
AdipoRon underwent apoptosis based on cleaved
caspase-3 and
annexin V staining.
AdipoRon treatment resulted in a dose dependent decrease in cell number versus vehicle treatment in OVCAR3 (-61.2%, P < 0.001), OVCAR4 (-79%, P < 0.001), and A2780 (-56.9%, P < 0.001). Ex vivo culture of primary
tumors treated with
AdipoRon resulted in an increase in apoptosis measured with cleaved
caspase-3 immunohistochemistry.
AdipoRon induces activation of AMPK and exhibits an anti-
tumor effect in
ovarian cancer cell lines and primary
tumor via a mTOR-independent pathway.